HK Stock Market Move | GENSCRIPT BIO (01548) rose more than 4% in the afternoon, with first quarter CARVYKTI sales netting $597 million, a year-on-year increase of over 60%.

GENSCRIPT BIO (01548) surged more than 4% in the afternoon, rising 3.78% as of press time to 13.18 Hong Kong dollars, with a turnover of 93.4181 million Hong Kong dollars. In terms of news, GENSCRIPT BIO announced that its subsidiary Legend Biotech generated a net sales of approximately 597 million US dollars in the first quarter ending in March under the cooperation and licensing agreement with Janssen Biotech, an increase of 61.8% year-on-year. China Securities Co., Ltd. released a research report stating that GENSCRIPT BIO's performance in 2025 is impressive, with growth in all three major segments. The life science segment continues to strengthen the flywheel effect of the platform, the integration of genes to proteins drives growth, and the global layout of automated production capacity accelerates. Percentage of innovative products from Biogenes continues to increase, commercialization of sweet proteins is accelerating, and AI-enabled R&D optimization is significantly effective. The robust growth of the CDMO business at Pongbor Bio is clearly recovering, with an acceleration in new orders, an increase in the percentage of overseas customers, and proprietary in vivo CAR-T platforms and innovative molecular assets expected to open up new growth opportunities.